BioLife Solutions, Inc. (BLFS) Earnings Call Analysis

NASDAQ · Healthcare · Medical Instruments & Supplies

Earnings Reports

• BioLife Solutions (BLFS) Q1 2026: BPM Revenue Jumps 25% as Commercial Therapy Penetration Deepens
  June 17, 2026
• BioLife Solutions (BLFS) Q2 2025: Cell Processing Revenue Up 28% as BPM Share Hits 70% of U.S. CGT Trials
  June 16, 2026
• BioLife Solutions (BLFS) Q3 2025: Cell Processing Revenue Jumps 33% as Pure Play Model Takes Hold
  June 16, 2026
• BioLife Solutions (BLFS) Q1 2025: Cell Processing Revenue Jumps 33% as Commercial Adoption Deepens
  July 05, 2025
• BioLife Solutions (BLFS) Q3 2024: Cell Processing Revenue Jumps 43% as SciSafe Exit Sharpens Focus
  November 12, 2024
• BioLife Solutions (BLFS) Q2 2024: Cell Processing Revenue Climbs 11% as Freezer Exit Sharpens Margin Focus
  August 08, 2024
• BioLife Solutions (BLFS) Q1 2024: GCI Divestiture Drives 13% Pro Forma EBITDA Margin, Refocuses on High-Growth Core
  May 09, 2024
• BioLife Solutions (BLFS) Q4 2023: Freezer Exit to Lift Margins as Cell Processing Climbs 11% Sequentially
  February 29, 2024
• BioLife Solutions (BLFS) Q3 2023: Cell Processing Down 26% as Freezer Divestiture Nears Completion
  November 09, 2023

Browse all companies